Abstracts tagged "methotrexate (MTX) and therapy"

Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 1882 • 2016 ACR/ARHP Annual Meeting
Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)
Walter A. Sifuentes-Giraldo¹, Dolors Grados Canovas², Marina De Los Riscos Alvarez³, María Pascual Pastor⁴, Pablo Moreno Fresneda⁵, Estibaliz Loza⁶, María J. García Yébenes⁶, Alejandro Olivé², Patricia Carreira Delgado³, Francisco J. Narvaez Garcia⁴, Rosario García-Vicuña⁷ and Antonio Zea Mendoza¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Eosinophilic fasciitis (EF) is a rare scleroderma-like disorder described in 1974 by Shulman. It is characterized by the acute onset of edema and induration…
Abstract Number: 958 • 2015 ACR/ARHP Annual Meeting
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Jens Klotsche¹, Gerd Ganser², Ivan Foeldvari³, Hans Huppertz⁴, Rolf M. Kuester⁵, Angelika Thon⁶, Kirsten Minden⁷ and Gerd Horneff⁸, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁴Prof Hess Children’s Hospital, Bremen, Germany, ⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ⁶Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, ⁷Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].